Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06829537 · ClinicalTrials.gov registry record
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
A clinical trial, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- 1,143
- Enrollment target
NCT06829537: Completed study, sponsored by Corcept Therapeutics.
NCT06829537 is a clinical trial that has completed, run by Corcept Therapeutics. The registered enrollment target is 1,143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06829537 has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- 1,143 participants
- Enrollment target
Study Summary
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethasone the night before at 11 PM. Cortisol level and study labs will also be collected. After the lab results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting blood draw at 8 AM and scheduling of a non-contrast CT scan.
Primary Outcome
Prevalence of endogenous hypercortisolism in a population with resistant hypertension will be described as the percentage of patients with post-DST cortisol \> 1.8 μg/dL with dexamethasone level ≥ 140 ng/dL among all patients enrolled.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,143 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2026-01-23 |
What the finished NCT06829537 record still lists
NCT06829537 is an observational study that tracks outcomes without assigning an intervention. Its 1,143 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06829537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06829537 about?
NCT06829537 is a clinical study titled "Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)". This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. Aft...
What is the current status of trial NCT06829537?
This trial is currently completed. The enrollment target is 1,143 participants. The study started on 2025-03-28. Estimated completion is 2026-01-23.
Who is sponsoring clinical trial NCT06829537?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI